German generic and branded drugmaker Stada Arzneimittel (SAZ: GR) reported first-half 2012 financial results, showing that group sales grew 7% year-on-year to 885.2 million euros ($1.09 billion).
Adjusted EBITDA and adjusted earnings per share both rise to 176.7 million euros (+10%) and 1.19 euros (+7%), respectively. One-time special effects in the amount of 25.7 million euros before taxes primarily due to the planned continuation of the cost efficiency program “STADA – build the future”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze